You might be surprised by the biggest operational barrier for biosimilars. But with a lower price than its brand-name reference products, would the inconvenience be worth the reward? With a survey of 25 health plan stakeholders, Dan Danielson, Cynthia Miller and Christopher Terrone discover more than half of the participants feel confident their organization can switch to biosimilars. So, why aren’t they? Find out in their recent conversation with Managed Healthcare Executive.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
